JP2023525571A5 - - Google Patents

Info

Publication number
JP2023525571A5
JP2023525571A5 JP2022568965A JP2022568965A JP2023525571A5 JP 2023525571 A5 JP2023525571 A5 JP 2023525571A5 JP 2022568965 A JP2022568965 A JP 2022568965A JP 2022568965 A JP2022568965 A JP 2022568965A JP 2023525571 A5 JP2023525571 A5 JP 2023525571A5
Authority
JP
Japan
Prior art keywords
agonist
pharmaceutical composition
thrβ
alkyl
fxr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568965A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525571A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/032085 external-priority patent/WO2021231646A1/en
Publication of JP2023525571A publication Critical patent/JP2023525571A/ja
Publication of JP2023525571A5 publication Critical patent/JP2023525571A5/ja
Pending legal-status Critical Current

Links

JP2022568965A 2020-05-13 2021-05-12 肝障害の併用処置 Pending JP2023525571A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063024360P 2020-05-13 2020-05-13
US63/024,360 2020-05-13
PCT/US2021/032085 WO2021231646A1 (en) 2020-05-13 2021-05-12 Combination treatment of liver disorders

Publications (2)

Publication Number Publication Date
JP2023525571A JP2023525571A (ja) 2023-06-16
JP2023525571A5 true JP2023525571A5 (https=) 2024-05-22

Family

ID=78524975

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568965A Pending JP2023525571A (ja) 2020-05-13 2021-05-12 肝障害の併用処置

Country Status (12)

Country Link
US (3) US20210379043A1 (https=)
EP (1) EP4149452A4 (https=)
JP (1) JP2023525571A (https=)
KR (1) KR20230024277A (https=)
CN (1) CN115811972A (https=)
AU (1) AU2021273487A1 (https=)
BR (1) BR112022023048A2 (https=)
CA (1) CA3183413A1 (https=)
IL (1) IL298144A (https=)
MX (1) MX2022014238A (https=)
TW (1) TW202207928A (https=)
WO (1) WO2021231646A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021050945A1 (en) 2019-09-12 2021-03-18 Terns, Inc. Thyroid hormone receptor beta agonist compounds
CA3193057A1 (en) 2020-08-25 2022-03-03 Eli Lilly And Company Polymorphs of an ssao inhibitor
KR20230142523A (ko) * 2021-02-01 2023-10-11 마드리갈 파마슈티칼스, 인크. 간 장애 또는 지질 장애의 치료를 위한 로수바스타틴 및 레스메티롬의 치료용 조합
TWI845975B (zh) * 2021-07-06 2024-06-21 中國大陸商甘萊製藥有限公司 用於治療肝臟疾病的聯合治療
TW202315608A (zh) * 2021-07-06 2023-04-16 中國大陸商甘萊製藥有限公司 用於治療肝臟疾病的聯合治療
CN119013027A (zh) * 2021-11-11 2024-11-22 拓臻制药公司 用于治疗肝脏病症的SSAO抑制剂和THR-β激动剂的组合
PE20241327A1 (es) * 2021-11-11 2024-06-26 Terns Pharmaceuticals Inc Tratamiento de trastornos hepaticos con un agonista del thr-beta
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009001359A2 (en) * 2007-06-27 2008-12-31 Quark Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of pro-apoptotic genes
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
KR102374499B1 (ko) * 2014-04-11 2022-03-14 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash 의 치료
JP7618384B2 (ja) * 2017-02-21 2025-01-21 ジェンフィ Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ
WO2018208707A1 (en) * 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
ES3029158T3 (en) * 2018-06-12 2025-06-23 Xizang Haisco Pharmaceutical Co Ltd Thyroid hormone receptor agonists and uses thereof
EP3844156A4 (en) * 2018-08-30 2022-06-08 Terns Pharmaceuticals, Inc. TREATMENT OF HEPATIC DISORDERS
EA202190661A1 (ru) * 2018-09-18 2021-08-13 Метакрайн, Инк. Агонисты фарнезоидного х-рецептора для лечения заболевания
CN111320609A (zh) * 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途

Similar Documents

Publication Publication Date Title
JP2023525571A5 (https=)
JP2022512482A5 (https=)
JP2025116875A5 (https=)
TWI852999B (zh) 治療脂肪性肝病及/或脂肪性肝炎的方法
JP2022546471A5 (https=)
RU2011139643A (ru) Способ лечения неалкогольного стеатогепатита повышенными дозами урсодезоксихолевой кислоты
JP2004524312A5 (https=)
CN113365998A (zh) 用于parp抑制剂的吲哚并七元酰肟类似物
JP2019511476A (ja) Ｆｘｒアゴニストを使用するための方法
JP2009531280A5 (https=)
JP2012529483A5 (https=)
JP2009528375A5 (https=)
JP2023504415A5 (https=)
CN111214464A (zh) 包含15-hepe的组合物以及其使用方法
JP2009513713A5 (https=)
RU2005135441A (ru) Соединения для лечения метаболических расстройств
JP2021525787A5 (https=)
JP2024540142A5 (https=)
WO2021218638A1 (zh) 用于糖尿病及其并发症治疗的联合用药及其药物组合物
JP2024544538A5 (https=)
JP2025508359A5 (https=)
AU2017328999A1 (en) Combination of FXR agonists
JP2008530242A5 (https=)
JP2007525533A5 (https=)
RU2017137008A (ru) Антагонисты толл-подобного рецептора 4 и применение при аутоиммунных заболеваниях печени